Anthos Therapeutics is a clinical-stage biopharmaceutical company focused on the development and commercialization of genetically and pharmacologically validated innovative therapies to advance care for people living with cardiovascular and metabolic (CVM) diseases.

Anthos Therapeutics

Anthos Therapeutics is a clinical-stage biopharmaceutical company focused on the development and commercialization of genetically and pharmacologically validated innovative therapies to advance care for people living with cardiovascular and metabolic (CVM) diseases.Anthos Therapeutics aims to combine the agility of a biotech with the rigor of a large pharmaceutical company. Anthos Therapeutics was launched by Blackstone Life Sciences in 2019. 

Novo Seeds

Anthos Therapeutics’ CEO John Glasspool joined host Karen Jagoda on the #EmpoweredPatient Podcast. They discuss the bleeding risk associated with current #anticoagulants, and the potential benefits that a #hemostasis sparing #anticoagulant could offer patients. 

Listen: https://bit.ly/3L7FDfO

#anticoagulant #thrombosis #hemostasis #ClinicalDevelopment

Anthos Therapeutics’ CEO John Glasspool spoke with Daniel Levine about the development of #abelacimab, and the potential to uncouple the pathways for #thrombosis and #hemostasis by targeting #FactorXI.

Listen on #TheBioReport Podcast: https://bit.ly/3KRZxuR

#anticoagulant #thrombosis #hemostasis #ClinicalDevelopment

Anthos Therapeutics’ CMO Dan Bloomfield, MD, FACC, FAHA recently joined NPR’s Tech Nation, hosted by Moira Gunn, to discuss the current unmet needs in #anticoagulation and #abelacimab’s ability to provide effective anticoagulation with the potential for a lower bleeding risk.

Listen: https://bit.ly/3JzrtlQ
 
#anticoagulant #thrombosis #hemostasis #ClinicalDevelopment

Despite being a leading cause of death and disability worldwide, many people are unaware of venous #thromboembolism (VTE) and its associated health risks.
 
Educate yourself and others about #VTE with resources from WorldThrombosisDay & the International Society on Thrombosis and Haemostasis (ISTH): https://bit.ly/33SFSrY
 
#anticoagulant #thrombosis #hemostasis #ClinicalDevelopment

Anthos Therapeutics is developing the novel dual activity agent #abelacimab to target both #FactorXI and #FactorXIa, with the potential to turn our vision of hemostasis sparing #anticoagulation into reality.

Learn more about the promise of #FactorXI inhibition: https://bit.ly/3pZXcph

#anticoagulant #thrombosis #hemostasis #ClinicalDevelopment

According to the Centers for Disease Control and Prevention, 10 to 30% of people will die within one month of being diagnosed with venous thromboembolism. Our goal is to improve patient outcomes by developing a novel #anticoagulant with the potential to provide hemostasis-sparing anticoagulation.

Learn more about #VTE: https://bit.ly/3tL5aUz

#anticoagulant #thrombosis #hemostasis #ClinicalDevelopment

#ICYMI – Anthos Therapeutics CEO John Glasspool joined host Matthew Pillar on the BioProcess Online #BusinessOfBiotech #Podcast to discuss the clinical development of abelacimab and the potential for pipeline expansion to other areas of unmet need.
 
Listen: https://lnkd.in/dWh96btM
 
#anticoagulant #thrombosis #hemostasis #ClinicalDevelopment

We are pleased to announce that CEO John Glasspool was appointed to the Biotechnology Innovation Organization Board of Directors. John’s vast biotech experience and passion for helping patients will support BIO’s mission to drive a biotech revolution through education, collaboration, and advocacy.
 
Learn more: https://lnkd.in/gE69pKG
 
#anticoagulant #thrombosis #hemostasis #ClinicalDevelopment

February is #AmericanHeartMonth, a time to focus on #cardiovascular health and educate others about the risks of #HeartDisease. Anthos Therapeutics is a clinical stage #biopharma company committed to improving outcomes for patients with cardiovascular and metabolic diseases.
 
Get involved: https://lnkd.in/eETWjdV
 
#anticoagulant #thrombosis #hemostasis #ClinicalDevelopment

COM:ANTHOSTHERAPEUTICS

Anthos Therapeutics

Financials Not Available